Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage Commercial Development and Launch of Solithromycin and

Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage
Commercial Development and Launch of Solithromycin and Taksta(TM)

CHAPEL HILL, N.C., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP)
today announced the appointment of David Moore as executive vice president and
chief commercial officer (CCO) to manage the commercial development and launch
of solithromycin and Taksta(TM).

"We know that developing and executing on the right commercial plan is key to
marketing success even for highly differentiated products such as
solithromycin and Taksta," said Prabhavathi Fernandes, president and chief
executive officer of Cempra. "To that end, we plan to develop the commercial
infrastructure to market these products in acute care settings, such as
hospitals, and select specialty community settings. These markets typically
require relatively small and targeted sales forces, which a company the size
of Cempra can successfully manage, while likely partnering for the broader
U.S. community market as well as for markets outside the U.S. in which
partners have the necessary resources and are better positioned. David has the
right mix of commercial expertise across several therapeutic areas, including
antibiotics and the Orphan space, which will be put to good use as we develop
the commercial plans for Cempra. We expect to rely on his extensive experience
in launch planning, marketing in both the acute and primary care settings as
well as his significant capabilities in pricing and reimbursement discussions
with payors. He is a valuable and timely addition to Cempra."

Mr. Moore has spent over 15 years developing and managing pharmaceutical
commercial programs, with the majority of those years spent with the
Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson.
Mr. Moore has held leadership roles in key sales and marketing functions, and
was part of teams that developed and executed launch plans for several
prescription pharmaceuticals for both primary and acute care settings. He was
also responsible for developing payer value platforms for several therapeutic
areas including antibiotics, pain and women's health, in which he successfully
implemented pricing and reimbursement strategies with hospitals and managed
care organizations. Following his tenure at Johnson & Johnson, he was chief
business officer and vice president of Worldwide Commercial Operations of
Tranzyme, Inc., where he was responsible for building the commercial
organization as well as in- and out-licensing clinical-stage assets. Before
joining Cempra, he was the chief business officer of Ocera Therapeutics where
he was responsible for developing the commercial plans for an
Orphan-designated advanced liver disease product for both the community and
acute care markets. Mr. Moore received his B.Sc. in Biology from Towson
University and an M.B.A. from Lehigh University, and a second graduate degree
in Health Policy Excellence from Thomas Jefferson University.

"Joining Cempra is a great opportunity to create and execute commercial
strategies for two differentiated antibiotic assets that are needed by both
patients and the medical community," said Mr. Moore. "Solithromycin, with its
multiple dosing formats in development, broad use potential beyond
community-acquired bacterial pneumonia, such as pediatric infections,
infections during pregnancy, gonorrhea and chronic obstructive pulmonary
disease, has the potential to be a major new antibiotic. Taksta may enable the
U.S. to improve both treatment and quality of life for patients with
prosthetic joints infections and to reflect the standard of practice in
countries in which patients can avoid multiple orthopedic surgeries. I look
forward to working with the Cempra team to make these two antibiotics
commercial successes."

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a late clinical-stage pharmaceutical company
focused on developing antibiotics to treat critical bacterial infections in
patients in both acute and primary care settings. Cempra's two lead product
candidates are currently in advanced clinical development.Solithromycin
(CEM-101) is in two Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan.TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. TAKSTA was recently granted orphan drug designation for this
indication. Both product candidates seek to address the need for new
treatments targeting drug-resistant bacterial infections in the hospital and
in the community. The company also intends to use its series of proprietary
lead compounds from its novel macrolide library for uses such as the treatment
of chronic inflammatory diseases, endocrine diseases and gastric motility
disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause actual events or results to differ
materially. These risks and uncertainties include, among others: the results,
timing, costs and regulatory review of our studies and clinical trials; the
results of studies of our product candidates conducted by others; our ability
to obtain FDA approval of our product candidates; our dependence on the
success of solithromycin and Taksta; our need to obtain additional funding and
our ability to obtain future funding on acceptable terms; our anticipated
capital expenditures and our estimates regarding our capital requirements; the
possible impairment of, or inability to obtain, intellectual property rights
and the costs of obtaining such rights from third parties; and innovation by
our competitors. The reader is referred to the documents that we file from
time to time with the Securities and Exchange Commission.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Robert.flamm@russopartnersllc.com
        
         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
         Andreas.marathis@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.